Previous 10 | Next 10 |
LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , invites investors and the general public to attend its annual meeting of stoc...
Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is ...
MARIETTA, Ga. , May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) (" MiMedx " or the " Company "), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Company's board of directors (the " Board ") has a...
NetworkNewsWire Editorial Coverage : Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) ( GNPX Profile ) is leveraging its patented technology pla...
Shares of XOMA Corporation (XOMA) have lost over 90% of their value during the past 10 years and are in the red by roughly 30% in the past 12 months. In 2018, it was noted that, since formation (in 1981), the company burned through an astounding $1.2 billion of capital and failed to bring a dr...
Agenus, Inc. (AGEN) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Jennifer Buell – Chief Operating Officer Garo Armen – Chairman and Chief Executive Officer Dhan Chand – Senior Scientist Bruno Lucidi – Chief Executive O...
Control4 (NASDAQ: CTRL ) +40% on Q1 earnings . More news on: Control4 Corporation, The Stars Group Inc., Tapestry, Inc., Stocks on the move, Read more ...
Agenus ( AGEN ) Q1 results : Revenues: $80M. More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Agenus (NASDAQ: AGEN ): Q1 GAAP EPS of $0.12 beats by $0.41 . More news on: Agenus Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
LEXINGTON, Mass. , May 9, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided corporate updates and reported financial results for the first quarter of 2...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...